Spero Therapeutics Stock News

SPR206 shown to be well-tolerated; achieved lung exposures consistent with predicted therapeutic levels, when administered three times daily at 100 mg

Spero Therapeutics <> said the Biomedical Advanced Research and Development Authority ((BARDA)) awarded up to an additional $12.9M to the company to to develop tebipenem as…

New award option exercised by BARDA brings the total potential funding from its existing contract with Spero up to $59.7 million New award option exercised by BARDA brings the total potential funding

Spero Therapeutics Inc (SPRO) shares closed today 10.6% higher than it did at the end of yesterday. The stock is currently down 17.6% year-to-date, down 19.8% over the past 12 months, and up 587.5% over the past five years. Today, the Dow Jones Industrial Average fell 0.6%, and the S&P 500 rose 0.0%. Trading Activity Shares traded as high as $13.45 and as low as $11.69 this week.Shares closed 40.6% below its 52-week high and 12.9% above its 52-week low.Trading volume this week was 6.3% higher than the 10-day average and 2.2% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and beats it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and beats it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 334.8% The company's stock price performance over the past 12 months lags the peer average by -1539.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Spero Therapeutics Inc (SPRO) shares closed today 10.6% higher than it did at the end of yesterday. The stock is currently down 25.5% year-to-date, down 25.8% over the past 12 months, and up 521.4% over the past five years. Today, the Dow Jones Industrial Average fell 0.6%, and the S&P 500 rose 0.0%. Trading Activity Shares traded as high as $13.45 and as low as $11.69 this week.Shares closed 40.6% below its 52-week high and 12.3% above its 52-week low.Trading volume this week was 12.9% higher than the 10-day average and 1.2% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 4.3% higher than its 5-day moving average, 4.3% lower than its 20-day moving average, and 18.1% lower than its 90-day moving average. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and beats it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and beats it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 511.5% The company's stock price performance over the past 12 months lags the peer average by -1122.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Spero's (SPRO) NDA for tebipenem HBr oral tablets for complicated urinary tract infections gets Priority Review.

CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Pha

The FDA has lifted the clinical hold on Spero Therapeutics Inc's (NASDAQ: SPRO) Phase 2 trial of SPR720 for nontuberculous mycobacterial (NTM) disease. The SPR720 program was placed on a clinical

Spero's (SPRO) NDA for tebipenem HBr oral tablets for complicated urinary tract infections gets Priority Review.

The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 27, 2022 The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 27, 2022

Shares of Spero Therapeutics, Inc. (NASDAQ:SPRO) crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $15.95 and traded as low as $13.27. Spero Therapeutics shares last traded at $13.65, with a volume of 107,572 shares trading hands. Several brokerages have recently issued reports on SPRO. […]

California State Teachers Retirement System grew its stake in Spero Therapeutics, Inc. (NASDAQ:SPRO) by 8.2% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 33,446 shares of the companys stock after purchasing an additional 2,523 shares during the period. California State []

CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercial

CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the Piper Sandler 33 rd Annual Virtual Healthcare Conference and the 4 th Annual Evercore ISI HealthCONx Conference, which are taking place virtually, November 29, 2021 through December 2, 2021 and November 30, 2021 through December 2, 2021, respectively. Details for the presentations are as follows.

CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializ